Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT1PM4)

• Drug Name: 4-[(diphenylmethyl)amino]-2-phenylquinazoline Drug Info
• Synonyms: 4-[(Diphenylmethyl)amino]-2-phenylquinazoline; CHEMBL305876; Benzhydryl-(2-phenyl-quinazolin-4-yl)-amine; SCHEMBL18388787; BDBM50116317

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9930153
  TTD Drug ID: DMT1PM4

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine transporter (DAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[2]
Dasotraline	DMLDQFV	Attention deficit hyperactivity disorder	6A05.Z	Approved	[3]
Methylphenidate	DM7SJD6	Attention deficit hyperactivity disorder	6A05.Z	Approved	[4]
Modafinil	DMYILBE	Malignant glioma	2A00.0	Approved	[5]
Phenmetrazine	DMXYTN9	Obesity	5B81	Approved	[6]
Ioflupane i-123	DMNARJT	Parkinson disease	8A00.0	Approved	[7]
DEXMETHYLPHENIDATE HYDROCHLORIDE	DM8WBAH	Attention deficit hyperactivity disorder	6A05.Z	Approved	[8]
Altropane	DMO9WDS	Attention deficit hyperactivity disorder	6A05.Z	Approved	[9]
Amitifadine	DMS1X67	Obesity	5B81	Phase 3	[10]
NAV5001	DMRSI1M	Dementia	6D80-6D86	Phase 3	[9]

Drug(s) Targeting Angiotensin II receptor type-1 (AGTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Losartan	DM72JXH	Diabetic kidney disease	GB61.Z	Approved	[11]
Olmesartan medoxomil	DMWBHRY	High blood pressure	BA00	Approved	[12]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[11]
Valsartan	DMREUQ6	Chronic heart failure	BD1Z	Approved	[11]
Candesartan	DMRK8OT	Chronic heart failure	BD1Z	Approved	[13]
Telmisartan	DMS3GX2	Hypertension	BA00-BA04	Approved	[14]
ANGIOTENSIN II	DMLWQ27	Increase blood pressure	BA04	Approved	[15]
SARALASIN	DMKS1DV	Hypertension	BA00-BA04	Approved	[16]
Tasosartan	DMM13DI	Hypertension	BA00-BA04	Approved	[17]
Eprosartan	DM07K2I	Hypertension	BA00-BA04	Approved	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin II receptor type-1 (AGTR1)	TT8DBY3	AGTR1_HUMAN	Antagonist	[1]
Dopamine transporter (DAT)	TTVBI8W	SC6A3_HUMAN	Inhibitor	[1]

References

• [1] Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8.
• [2] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [3] Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
• [4] Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
• [9] Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
• [11] Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
• [12] Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56.
• [13] Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007.
• [14] Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35.
• [15] The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
• [16] Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
• [17] Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.
• [18] Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7.